Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Lucid Diagnostics's Enterprise Value is $215.10 Mil.
Lucid Diagnostics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-44.99 Mil. Therefore, Lucid Diagnostics's EV-to-EBIT ratio for today is -4.78.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Lucid Diagnostics's Enterprise Value is $215.10 Mil.
Lucid Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-44.12 Mil. Therefore, Lucid Diagnostics's EV-to-EBITDA ratio for today is -4.88.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Lucid Diagnostics's Enterprise Value is $215.10 Mil.
Lucid Diagnostics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $5.13 Mil. Therefore, Lucid Diagnostics's EV-to-Revenue ratio for today is 41.90.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Lucid Diagnostics (NAS:LUCD) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Lucid Diagnostics's current Enterprise Value is $215.10 Mil.
Lucid Diagnostics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44.99 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Lucid Diagnostics's current Enterprise Value is $215.10 Mil.
Lucid Diagnostics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-44.12 Mil.
Lucid Diagnostics's current Enterprise Value is $215.10 Mil.
Lucid Diagnostics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.13 Mil.
Lucid Diagnostics's current Enterprise Value is $215.10 Mil.
Lucid Diagnostics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.12 Mil.
Lucid Diagnostics's current Enterprise Value is $215.10 Mil.
Lucid Diagnostics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-46.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics Enterprise Value Related Terms
Lucid Diagnostics Enterprise Value Historical Data
* Premium members only.
The historical data trend for Lucid Diagnostics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUCD vs TLSI, INFU, TANAF: Enterprise Value Comparison
For the Medical Devices subindustry, Lucid Diagnostics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lucid Diagnostics Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Lucid Diagnostics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Lucid Diagnostics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Lucid Diagnostics's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lucid Diagnostics (LUCD) has a Enterprise Value of $215.10 Mil as of Jun. 26, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Lucid Diagnostics and its competitors.
Is Lucid Diagnostics' Enterprise Value too high?
Lucid Diagnostics' current Enterprise Value is $215.10 Mil. Overall, Lucid Diagnostics has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lucid Diagnostics' Enterprise Value compare to TLSI and INFU?
Lucid Diagnostics' Enterprise Value of $215.10 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Lucid Diagnostics and its competitors. Lucid Diagnostics's current Enterprise Value is $215.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lucid Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Lucid Diagnostics (LUCD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.81, compared to a current price of $1.07 — trading 31.5% above its estimated fair value. The current Enterprise Value is $215.10 Mil. Lucid Diagnostics' overall GF Score™ is 26/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Lucid Diagnostics (LUCD), the current Enterprise Value is $215.10 Mil as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lucid Diagnostics (LUCD) Overvalued in 2026?
Based on GuruFocus' analysis, Lucid Diagnostics stock appears to be overvalued.
The current stock price of $1.07 is trading 31.5% above its estimated GF Value™ of $0.81.
GuruFocus considers Lucid Diagnostics to be Significantly Overvalued.
Key valuation signals for LUCD:
Enterprise Value: $215.10 Mil
GF Value™: $0.81 vs. price of $1.07 (31.5% above fair value)
No single metric tells the full story. See the LUCD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
26GF Score
Get the complete analysis for LUCD
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUCD has been successfully added to your 
